Loading...
DR Reddys Laboratories Limited — Tacrolimus Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #9 for Tacrolimus · $1.4M export value · DGFT Verified
DR Reddys Laboratories Limited is the #9 Indian exporter of Tacrolimus with $1.4M in export value and 27 verified shipments. DR Reddys Laboratories Limited holds a 0.7% market share in Tacrolimus exports across 2 countries. The company exports 37 pharmaceutical products worth $62.4M across 17 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.1M | 24 | 87.7% |
| SAUDI ARABIA | $150.0K | 3 | 12.3% |
DR Reddys Laboratories Limited exports Tacrolimus to 2 countries. The largest destination is UNITED STATES accounting for 87.7% of DR Reddys Laboratories Limited's Tacrolimus shipments. These destinations reflect DR Reddys Laboratories Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| DR REDDYS LABORATORIES INC | UNITED STATES | $500.0K | 10 |
| DR REDDY SLABORATORIES INC | UNITED STATES | $421.2K | 11 |
| SAUDI PHARMACEUTICAL IND MED APPL CORP SPIMACO ADDWAEIH | SAUDI ARABIA | $150.0K | 3 |
| PRIORITY HEALTHCARE DISTRIBUTION DBA CURASCRIPT | UNITED STATES | $150.0K | 3 |
DR Reddys Laboratories Limited supplies Tacrolimus to 4 buyers globally. The largest buyer is DR REDDYS LABORATORIES INC (UNITED STATES), followed by DR REDDY SLABORATORIES INC (UNITED STATES) and SAUDI PHARMACEUTICAL IND MED APPL CORP SPIMACO ADDWAEIH (SAUDI ARABIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $92.4M worth of Tacrolimus through 4,611 shipments from 299 suppliers to 127 countries, serving 727 buyers globally. DR Reddys Laboratories Limited contributes $1.4M to this total, accounting for 0.7% of India's Tacrolimus exports. DR Reddys Laboratories Limited ships Tacrolimus to 2 countries through 4 buyers.
DR Reddys Laboratories Limited's average Tacrolimus shipment value is $50.0K per consignment, based on 27 shipments totaling $1.4M. The largest destination is UNITED STATES (87.7% of DR Reddys Laboratories Limited's Tacrolimus exports).
DR Reddys Laboratories Limited ranks #9 among 299 Indian Tacrolimus exporters with a 0.7% market share. The top 3 exporters are SANDOZ PRIVATE LIMITED ($36.9M), INTAS PHARMACEUTICALS LIMITED ($22.5M), ALKEM LABORATORIES LIMITED ($8.4M). DR Reddys Laboratories Limited processed 27 shipments to 2 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TACROLIMUS CAPSULES USP 1MG 100S 35098X 100S PACKS=3509800 NOS | $150.0K | 3 |
| TACROLIMUS CAPSULES USP 0.5MG 100S 21723 X 100S PACKS=2172300 NOS | $150.0K | 3 |
| CROTAL 5.0 MG TACROLIMUS CAPSULES 5 MG50'S PACK 6240 X 50'S PACK = 312000NO'S | $50.0K | 1 |
| CROTAL 1 MG TACROLIMUS CAPSULES 1 MG 50'S PACK 33594 X 50'S PACK = 1679700NO'S | $50.0K | 1 |
| CROTAL 1 MG TACROLIMUS CAPSULES 1 MG 50'S PACK 49626 X 50'S PACK = 2481300NO'S | $50.0K | 1 |
| TACROLIMUS CAPSULES USP 1MG 100S 8736 | $50.0K | 1 |
| TACROLIMUS CAPSULES USP 1MG 100 S 8760X 100 S PACKS = 876000 NOS | $50.0K | 1 |
| 300009517 TACROLIMUS CAPSULES USP 1MG 100S 8746 SU X 100=874600 NOS | $50.0K |
What DR Reddys Laboratories Limited must comply with to export Tacrolimus to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 13 | ENCUBE ETHICALS PRIVATE LIMITED | $2.0M | 44 | 1 | $45.1K |
| 10 | CARITAS HEALTHCARE PRIVATE LIMITED | $1.7M | 34 | 2 | $50.0K |
| 9 | DR REDDYS LABORATORIES LIMITED ★ | $1.4M | 27 | 2 | $50.0K |
| 15 | DR.REDDY'S LABORATORIES LIMITED | $1.1M | 34 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 741 | 16.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 645 | 14.0% |
| DELHI AIR CARGO ACC (INDEL4) | 398 | 8.6% |
| NHAVA SHEVA SEA (INNSA1) | 358 | 7.8% |
| DELHI AIR | 320 | 6.9% |
| AHEMDABAD AIR ACC (INAMD4) | 175 | 3.8% |
| JNPT/ NHAVA SHEVA SEA | 169 | 3.7% |
| Bombay Air | 141 | 3.1% |
DR Reddys Laboratories Limited also exports these immunosuppressants products. Each links to the detailed product page.
The global pharmaceutical export landscape has been significantly influenced by recent geopolitical events. The 2026 Strait of Hormuz crisis, initiated by military conflicts involving the United States, Israel, and Iran, led to the effective halt of shipping traffic through this critical maritime route, disrupting approximately 20% of the world's daily oil supply and causing a surge in global energy prices. (en.wikipedia.org) This disruption has had a cascading effect on shipping costs and insurance premiums, directly impacting Indian pharmaceutical exporters like Dr. Reddy's, which rely on these routes for timely delivery of products to key markets.
Simultaneously, the 2025–26 United States–India diplomatic and trade crisis, marked by the imposition of a 50% tariff on Indian exports by the U.S., has posed additional challenges. These tariffs have increased the cost of Indian pharmaceutical products in the U.S. market, potentially affecting the competitiveness of companies like Dr. Reddy's. (en.wikipedia.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. Dr. Reddy's has been proactive in adhering to these regulations, ensuring that its products meet the stringent safety and traceability standards mandated by the EU, thereby maintaining its market access and reputation.
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Dr. Reddy's has demonstrated a commitment to quality by securing approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Medicines Agency (EMA). The company's recent Biologics License Application (BLA) submission for a proposed interchangeable biosimilar to Orencia® (abatacept) underscores its adherence to rigorous regulatory processes. (stockwatch.com)
However, the company has faced regulatory challenges, such as the tax audit decision from the Russian Federal Tax Service in January 2026, which reclassified certain marketing services as taxable, resulting in a penalty. (stocktitan.net) Such incidents highlight the complexities of operating in diverse regulatory environments and the importance of robust compliance frameworks.
DR Reddys Laboratories Limited exports 37 products worth $62.4M. Beyond Tacrolimus, top products include Omeprazole, Metoprolol, Diclofenac, Clopidogrel, Fexofenadine. View the complete DR Reddys Laboratories Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Tacrolimus — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddys Laboratories Limited's Tacrolimus exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddys Laboratories Limited
Full Company Profile →
37 products · $62.4M total trade · 17 categories
| 1 |
| 300040091 Tacrolimus caps USP 1mg 100sQuallent USA Batch No.C23808769 16.04.2023/ 31.03.2026 8736 x 100 SU X 8.57 SU | $50.0K | 1 |
| 300040091 Tacrolimus caps USP 1mg 100sQuallent USA Batch No.C2308862 12.04.2023/ 31.03.2026 8736 x 100 SU X 8.57 SU | $50.0K | 1 |
DR Reddys Laboratories Limited exports 23 distinct Tacrolimus formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TACROLIMUS CAPSULES USP 1MG 100S 35098X 100S PACKS=3509800 N with 3 shipments worth $150.0K.
| 2 |
| $33.0K |
| 7 | BIOCON PHARMA LIMITED | $1.1M | 22 | 2 | $50.0K |
DR Reddys Laboratories Limited ranks #9 among 299 Indian Tacrolimus exporters. Average shipment value of $50.0K compared to the market average of $309.1K. The closest competitors by value are ENCUBE ETHICALS PRIVATE LIMITED and CARITAS HEALTHCARE PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 127+ countries, 727+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for DR Reddys Laboratories Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Tacrolimus. For current shipment-level data, contact TransData Nexus.